COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes (EFFECTIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00699179
Recruitment Status : Completed
First Posted : June 17, 2008
Last Update Posted : October 31, 2016
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This study is conducted in Europe. This observational study is aimed to reflect the post-authorisation experience with insulin analogue (biphasic insulin aspart 30) when used under normal clinical practice conditions in Serbia.

Condition or disease Intervention/treatment
Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Drug: biphasic insulin aspart 30

Layout table for study information
Study Type : Observational
Actual Enrollment : 2308 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: EFFicacious glycaEmia Control, Treatment Goal achIevement Very simplE With NovoMix 30: A Single-country, Multicentre, Prospective, Open Label, Non-controlled, Observational, 26-week Study in Serbian Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Diabetes Mellitus in Everyday Clinical Practice
Study Start Date : June 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
A Drug: biphasic insulin aspart 30
There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
Other Name: NovoMix® 30

Primary Outcome Measures :
  1. Change in HbA1c from baseline [ Time Frame: After 6 months ]

Secondary Outcome Measures :
  1. Percentage of patients achieving HbA1c below 7,5% for Type 1 Diabetes Mellitus, below 7.0% and below or equal to 6.5% for Type 2 Diabetes Mellitus [ Time Frame: after 12 weeks and 26 weeks compared to baseline ]
  2. Change in FPG (glucose variability) [ Time Frame: after 12 weeks and 26 weeks compared to baseline ]
  3. Change in PPG (postprandial control) [ Time Frame: after 12 weeks and 26 weeks compared to baseline ]
  4. Change in insulin dose and number of injections [ Time Frame: at 12 weeks and 26 weeks of treatment ]
  5. Change in oral antidiabetic drug therapy dosage and eventual discontinuation of oral antidiabetic drug therapy during the study [ Time Frame: after 12 weeks and 26 weeks of treatment compared to baseline ]
  6. Change in body weight and waist circumference [ Time Frame: at 12 weeks and 26 weeks of treatment compared to baseline ]
  7. Change in number of major hypoglycaemic events during 4 weeks proceeding routine visits [ Time Frame: at 12 weeks and 26 weeks of treatment compared to baseline ]
  8. Number of adverse drug reactions (ADR) [ Time Frame: after 12 weeks and 26 weeks of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Type 1 and 2 diabetes

Inclusion Criteria:

  • Type 1 or Type 2 Diabetes Mellitus inadequately controlled on human insulin therapy lasting for at least 6 months
  • HbA1c greater than 7%
  • Informed Consent

Exclusion Criteria:

  • Patients with a hypersensitivity to biphasic insulin aspart 30 or to any of the excipients
  • Other limiting conditions specified in the locally approved NovoMix 30 SPC ( Summary of Product Characteristics), PIL ( Patient Information Leaflet).
  • Women who are pregnant, breast feeding or have the intention of becoming pregnant within next couple of months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00699179

Layout table for location information
Former Serbia and Montenegro
Novo Nordisk Investigational Site
Belgrade, Former Serbia and Montenegro, 11 070
Sponsors and Collaborators
Novo Nordisk A/S
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Additional Information:
Layout table for additonal information
Responsible Party: Novo Nordisk A/S Identifier: NCT00699179    
Other Study ID Numbers: BIASP-3557
First Posted: June 17, 2008    Key Record Dates
Last Update Posted: October 31, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin Aspart
Biphasic Insulins
Insulin aspart, insulin aspart protamine drug combination 30:70
Hypoglycemic Agents
Physiological Effects of Drugs